Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study

Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high... Letters to the Editor 261 Dr Alfonso et al. conclude their letter with diagnosis). If an isolated CT/MRI abnormality doi:10.1093/eurheartj/ehp515 the recommendation of ‘indefinite dual anti- alone sufficed for the diagnosis of stroke, Online publish-ahead-of-print 27 November 2009 platelet regimen’ for late-stent malapposition then what if any is the clinical relevance in patients ‘unless an increased bleeding risk is the absence of clinical sequela? Furthermore, Effects of valsartan on perceive’. We cannot but in principle agree the PROBE design had the potential to bias morbidity and mortality in with this therapeutic proposal, given the fact the number of strokes diagnosed even if uncontrolled hypertensive that in our clinical setting we mostly observe the incidence of ‘silent’ strokes was similar patients with high ST in SM patients after they have terminated in both arms of the trial. If more CT/MRI the 12-month dual anti-platelet therapy. cardiovascular risks: KYOTO were performed in the non-ARB arm when However, our meta-analyses were not compared with the valsartan arm, regardless HEART Study designed to sustain this proposal while of for what symptoms, the number of abnor- In the KYOTO HEART study, valsartan future randomized trials may indeed confirm mal CT/MRI would be proportionally reduced http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Heart Journal Oxford University Press

Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study

European Heart Journal , Volume 31 (2) – Jan 27, 2010

Loading next page...
 
/lp/oxford-university-press/effects-of-valsartan-on-morbidity-and-mortality-in-uncontrolled-7itEC5iSIm

References (46)

Publisher
Oxford University Press
Copyright
© Published by Oxford University Press.
Subject
LETTERS TO THE EDITOR
ISSN
0195-668X
eISSN
1522-9645
DOI
10.1093/eurheartj/ehp515
pmid
19946109
Publisher site
See Article on Publisher Site

Abstract

Letters to the Editor 261 Dr Alfonso et al. conclude their letter with diagnosis). If an isolated CT/MRI abnormality doi:10.1093/eurheartj/ehp515 the recommendation of ‘indefinite dual anti- alone sufficed for the diagnosis of stroke, Online publish-ahead-of-print 27 November 2009 platelet regimen’ for late-stent malapposition then what if any is the clinical relevance in patients ‘unless an increased bleeding risk is the absence of clinical sequela? Furthermore, Effects of valsartan on perceive’. We cannot but in principle agree the PROBE design had the potential to bias morbidity and mortality in with this therapeutic proposal, given the fact the number of strokes diagnosed even if uncontrolled hypertensive that in our clinical setting we mostly observe the incidence of ‘silent’ strokes was similar patients with high ST in SM patients after they have terminated in both arms of the trial. If more CT/MRI the 12-month dual anti-platelet therapy. cardiovascular risks: KYOTO were performed in the non-ARB arm when However, our meta-analyses were not compared with the valsartan arm, regardless HEART Study designed to sustain this proposal while of for what symptoms, the number of abnor- In the KYOTO HEART study, valsartan future randomized trials may indeed confirm mal CT/MRI would be proportionally reduced

Journal

European Heart JournalOxford University Press

Published: Jan 27, 2010

There are no references for this article.